ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...
ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...
TipRanks on MSN
KALA BIO announces new CEO and funding deal
The latest update is out from KALA BIO ( (KALA) ).
Alcon has expanded its portfolio of eye disease products by paying $60 million upfront for the rights to two commercial products based on mucus-penetrating particle drug delivery technology. The sale ...
Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback